WANTAI BIOLOGICAL(SH:603392) Zheng Quan Ri Bao·2025-09-11 23:57Core Points - The Chinese government is focusing on high-quality health initiatives during the "14th Five-Year Plan," with significant achievements in disease prevention and control [1] - The introduction of HPV vaccination services for eligible girls is a key initiative aimed at protecting women's health [1] Group 1: HPV Vaccination Initiatives - The national health authority is implementing free HPV vaccination services across various regions, with a focus on accessibility and convenience for the public [2] - The HPV vaccine included in the national immunization program is a bivalent vaccine, primarily targeting HPV types 16 and 18, which account for 70% to 80% of cervical cancer cases [2] - Approximately 60% of eligible girls in China are covered by the free vaccination policy, which has been adopted in 18 provinces and several cities [2] Group 2: Domestic Vaccine Development - The domestic bivalent HPV vaccine has proven to be effective and cost-efficient, significantly lowering vaccination costs and facilitating the establishment of a large-scale immunity barrier [3] - The launch of the first domestically developed nine-valent HPV vaccine, "Xinkening 9," marks a significant advancement in cervical cancer prevention, providing a broader range of protection [3][5] - The nine-valent HPV vaccine is priced at 499 yuan per dose, which is less than half the cost of imported alternatives, making it more accessible [3] Group 3: Production and Safety - The domestic vaccine manufacturer, Wantai Biological Pharmacy, has produced over 100 million doses of the HPV vaccine, all of which have passed national quality checks [4] - Clinical studies have shown that the domestic nine-valent HPV vaccine has comparable safety and efficacy to imported products, with a 100% seroconversion rate for all HPV types tested [5] - The successful launch of the domestic nine-valent HPV vaccine is expected to alleviate supply shortages and enhance vaccination willingness among eligible women, contributing to the goal of eliminating cervical cancer by 2050 [5]